AMPEL is a precision medicine company commercializing LDTs that predict disease status, molecular pathways, and best drug options.
AMPEL BioSolutions has raised $1.8M in total funding. The most recent round was Debt Financing. The last funding was announced in July 2023.
AMPEL BioSolutions's investors include U.S. Small Business Administration.
AMPEL BioSolutions is headquartered in Charlottesville, United States.
AMPEL is a precision medicine company commercializing LDTs that predict disease status, molecular pathways, and best drug options.
AMPEL BioSolutions is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AMPEL BioSolutions — Funding & Investors." VCBacked, July 6, 2023, https://www.vcbacked.co/company/ampel-biosolutions. Accessed September 30, 2026.
VCBacked. (2023). AMPEL BioSolutions — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/ampel-biosolutions
{{cite web |title=AMPEL BioSolutions — Funding & Investors |url=https://www.vcbacked.co/company/ampel-biosolutions |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated